Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3 - A randomized, double-blind placebo-controlled study

Academic Article


  • The use of OKT3 as an immunosuppressive agent is accompanied by increased cytokine production and constellation of side effects collectively termed cytokine release syndrome (CRS). Pentoxifylline (PTF) inhibits synthesis of some cytokines, and has been shown to attenuate CRS when administered before OKT3. In this double-blinded, placebo-controlled study, 46 renal allograft recipients were randomized to receive either PTF (800 mg q 8 hr for at least 24 h) p.o. or placebo, along with methylprednisolone (7 mg/kg), diphenhydramine, and acetaminophen, prior to beginning OKT3 as therapy for acute rejection. Patients were observed, and symptoms scored semiquantitatively. Despite the presence of therapeutic PTF levels (721±726 ng/ml), the frequency and severity of side effects (fever, chills, headache, neurocortical symptoms, dyspnea, nausea, vomiting, diarrhea) did not differ between treatment groups. Likewise PTF did not affect renal function or immunologic response to OKT3, with similar graft and patient survival in both groups. Plasma levels of TNF α, IFN γ, IL-6, and IL-8 increased as predicted following OKT3 administration, without significant differences between PTF and placebo groups. In this controlled, multicenter trial, pretreatment with oral PTF was ineffective in attenuating OKT3-related CRS in renal allograft recipients.
  • Authors

    Published In

  • Transplantation  Journal
  • Digital Object Identifier (doi)

    Pubmed Id

  • 5862630
  • Author List

  • Vincenti F; Danovitch GM; Neylan JF; Steiner RW; Everson MP; Gaston RS
  • Start Page

  • 573
  • End Page

  • 577
  • Volume

  • 61
  • Issue

  • 4